Soluble complement receptor type 1 inhibits complement system activation and improves motor function in acute spinal...

Area of Science:

• Neuroscience
• Immunology
• Pharmacology

Background:

• Spinal cord injury (SCI) triggers inflammatory responses mediated by complement system activation.
• Soluble complement receptor type 1 (sCR1) is a potent inhibitor of complement cascade.
• Understanding the therapeutic potential of sCR1 in SCI is crucial.

Purpose of the Study:

• To investigate the efficacy of sCR1 in mitigating inflammation and improving motor function following experimental SCI in rats.
• To evaluate the impact of sCR1 on complement activation markers and inflammatory cell infiltration in injured spinal cord tissue.

Main Methods:

• A rat model of SCI was established using Sprague-Dawley rats.
• Animals were divided into three groups: sCR1 treatment, saline control, and sham operation.
• Immunohistochemistry for C9 and CD59, myeloperoxidase (MPO) activity assays, and motor function scoring (Basso, Beattie and Bresnahan scale) were performed.

Main Results:

• sCR1 administration significantly reduced the expression of C9 and CD59 in injured spinal cords compared to controls.
• Myeloperoxidase (MPO) activity, an indicator of neutrophil infiltration, was significantly decreased in the sCR1 group.
• Motor function scores were significantly improved in the sCR1-treated group by 7 days post-injury.

Conclusions:

• Soluble CR1 effectively inhibits complement system activation in the context of acute SCI.
• sCR1 treatment leads to reduced inflammation and significant improvement in motor recovery after spinal cord injury.
• sCR1 demonstrates therapeutic potential for managing acute SCI by modulating inflammatory pathways.